Results 241 to 250 of about 52,382 (294)

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial. [PDF]

Br J Haematol
Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Díez-Campelo M, de Paz R, Santillana GS, Thépot S, Kaźmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM.   +20 more
europepmc   +1 more source

A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice. [PDF]

Pract Lab Med
Wang X, Huang J, Xi J, Liu H, Yuan Y.
europepmc   +1 more source

Diagnosis of myelodysplastic syndromes: the classic and the novel. [PDF]

Haematologica
Oster HS, Van de Loosdrecht AA, Mittelman M.   +2 more
europepmc   +1 more source

The Role of Iron-Overloaded Macrophages in Mesenchymal Stem Cell Senescence and Anemia in Myelodysplastic Syndromes: Protocol for an In Vitro Study.

JMIR Res Protoc
Bai L, Wang F, Jiang Y, Ouyang H.
europepmc   +1 more source

Treatment of lower-risk myelodysplastic syndromes. [PDF]

Haematologica
Merz AMA, Platzbecker U.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Myelodysplastic syndromes

Lancet, The, 2014
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.
Lionel Adès, Raphael A Itzykson, Pierre Fenaux   +2 more
exaly   +3 more sources

Myelodysplastic Syndromes

Annals of the New York Academy of Sciences, 2004
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela, MESSA F, CARTURAN S, ARRUGA F, DEFILIPPI I, MESSA E, GOTTARDI E, SAGLIO, Giuseppe   +7 more
  +8 more sources

Myelodysplastic syndromes

Hematology and Cell Therapy, 1996
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel, G F, Sanz, T, Vallespí, M C, del Cañizo, M A, Sanz   +4 more
  +9 more sources

Myelodysplastic syndromes

Nature Reviews Disease Primers, 2022
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres, Yang Liang   +4 more
openaire   +2 more sources